Analyst Summary: ALX Oncology Holdings Inc. (NASDAQ: ALXO) reported its financial results for Q4 and FY2022, revealing the company's continued clinical development success. The biopharmaceutical firm's founder and CEO, Dr. Jaume Pons, identified the advancement of its leading product, evorpacept, for multiple solid tumor indications and hematological malignancies, as a significant accomplishment. ALX Oncology aims to submit its Investigational New Drug application for ALTA-002, a new pipeline product for gastrointestinal cancer, in H1 2023. Meanwhile, clinical trials for ASPEN-03 and ASPEN-04 continue as planned for the treatment of advanced head and neck cancers. The company also strengthened its board of directors with the addition of a new independent board member, Scott Garland. Financially, the company has $100 million in non-dilutive financing, with $40 million available for use through the end of 2023. Notably, ALX Oncology reported no revenues for this quarter and the preceding year. Investors should take note of the company's continued progress, although they should exercise caution as to forward-looking statements, not least with the lack of revenues.